Despite the clinical benefits of ADT for the treatment of PCa, emerging evidence has suggested that ADT propels the cancer cells toward therapy-induced resistance and emergence of aggressive AR-independent variants of prostate cancer. This evidence concerns the gene AR and prostate cancer.